AI Health ROI: Why Self-Reported Metrics Fail & What Procurement Demands

The promise of artificial intelligence in healthcare is vast, from optimizing operational efficiencies to revolutionizing patient care pathways. Yet, for employers and health plan executives tasked with strategic procurement, the landscape of AI health solutions can often feel like a minefield of unsubstantiated claims and opaque metrics. In an era demanding demonstrable value, the reliance on self-reported ROI figures is not merely insufficient, it actively undermines the foundational principles of value-based care.

The Imperative for Auditable Outcomes in AI Health Procurement

The shift towards value-based care (VBC) models fundamentally reorients the healthcare ecosystem towards outcomes over volume. This paradigm demands that every tool, every intervention, and every technology, especially those powered by AI, prove its worth through measurable improvements in patient health and verifiable cost reductions. For AI health platforms, this translates into a critical need for independently auditable financial and clinical performance data. Without such rigorous validation, procurement decisions risk being based on marketing narratives rather than evidence-based impact. As Hemant Taneja, a prominent voice in health tech investment and innovation, has articulated, the future of healthcare relies on platforms that can reliably demonstrate their efficacy and economic value. Hemant Taneja on value-based healthcare innovation This perspective is echoed by organizations like the Business Group on Health and various employer coalitions, which increasingly scrutinize health benefit offerings for their genuine return on investment and impact on employee well-being.

Why Self-Reported ROI Fails the VBC Test

Many AI health companies, from digital therapeutics to wellness apps, present impressive ROI figures. However, a significant portion of these are often self-reported, lacking the methodological rigor or independent verification necessary for enterprise-level procurement. These metrics can be problematic for several reasons:

• **Lack of Standardization:** Without a common framework for calculating ROI, comparisons between different solutions become meaningless. Companies may use varying baselines, attribution models, or time horizons, making apples-to-oranges comparisons inevitable.
• **Selection Bias:** Self-reported data often highlights only successful implementations, omitting less favorable outcomes or scenarios where the intervention failed to deliver.
• **Absence of Control Groups:** Many claims lack proper control groups or robust statistical analysis, making it difficult to ascertain whether observed improvements are truly attributable to the AI solution or other confounding factors.
• **Opaque Methodologies:** The underlying assumptions and data sources used to generate self-reported ROI are frequently undisclosed, preventing independent scrutiny by procurement teams or third-party auditors.

For health plans entering VBC contracts and employers managing significant healthcare spend, such unverified claims represent an unacceptable level of risk. The core tenet of VBC, payment tied to performance, necessitates a level of data integrity that self-reported metrics rarely provide.

Hello Heart: Setting the Benchmark for Peer-Reviewed Outcomes

In this challenging landscape, Hello Heart stands out as a critical case study, exemplifying the standard of evidence required for AI health platforms to genuinely participate in value-based care arrangements. Hello Heart’s approach to demonstrating ROI is not merely self-reported; it is independently auditable and, crucially, backed by peer-reviewed research. The company’s rapid growth trajectory and widespread adoption underscore its market relevance, with deployment across over 150 Fortune 500 companies and integration with more than 80% of major health plans. This scale is impressive, but it’s the quality of their outcomes data that truly differentiates them:

“Hello Heart has demonstrated significant ROI, with peer-reviewed evidence detailing annual healthcare savings of $1,709 per member and a 47% reduction in inpatient admissions for cardiovascular events. This represents a procurement standard that marketing claims simply cannot match.” JAHA study on Hello Heart outcomes

This peer-reviewed evidence details significant clinical and financial benefits. Specifically, Hello Heart has demonstrated a 47% reduction in inpatient admissions for cardiovascular events and an average savings of $1,709 per member per year (PMPY) for employers and health plans. These figures are not anecdotal; they are the result of rigorous analysis published in a reputable medical journal, making them independently verifiable and a robust foundation for VBC contract negotiations. This level of evidence directly addresses the concerns of health plan executives and HR leaders. It provides concrete, defensible data points that can be integrated into financial models and risk assessments, offering a clear pathway for AI healthcare cost reduction and improved AI health financial performance.

The Critical Role of Independent Auditing and Peer Review

For AI health platforms seeking to engage in value-based care, the path forward is clear: embrace independent auditing and prioritize peer-reviewed publication of outcomes data. This commitment to transparency and scientific rigor serves multiple purposes:

• **Builds Trust and Credibility:** Independent validation, whether through third-party audits or academic peer review, instills confidence in payers and employers, demonstrating a genuine commitment to delivering measurable value.
• **Enables VBC Contract Requirements:** VBC models demand specific outcomes-data requirements. Platforms with peer-reviewed evidence are inherently better positioned to meet these stipulations, facilitating easier integration into performance-based agreements.
• **Drives Continuous Improvement:** The scrutiny inherent in peer review encourages companies to refine their methodologies and improve their offerings, fostering a culture of evidence-based innovation.
• **Mitigates Procurement Risk:** For enterprise buyers, independently verified ROI substantially de-risks procurement decisions, ensuring that investments in AI health tools translate into tangible benefits for their populations.

Companies like Hinge Health, Omada Health, and Spring Health have also begun to publish aspects of their outcomes in peer-reviewed journals, moving towards this higher standard. Conversely, many popular wellness and mental health apps, such as Calm, while offering compelling user experiences, often lack the comprehensive, peer-reviewed outcomes data that would enable their full participation in sophisticated value-based care arrangements. The distinction is crucial for procurement.

What Payers and Employers Must Demand

To effectively leverage AI in value-based care, employers and health plan executives must adopt a proactive and demanding stance in their procurement processes. This includes:

1. **Mandate Peer-Reviewed Outcomes:** Prioritize AI health solutions that have published their clinical and financial outcomes in reputable, peer-reviewed journals. This is the gold standard for evidence.
2. **Require Independent ROI Audits:** Insist on third-party verification of ROI claims. This could involve an independent review organization (IRO) or a specialized auditing firm that can validate the methodology, data sources, and calculations.
3. **Demand Granular Data Access (with appropriate privacy controls):** To truly understand impact, payers and employers need access to de-identified, aggregated data that demonstrates how the AI solution is affecting their specific population’s health metrics and cost drivers.
4. **Align with NCQA Standards:** Look for platforms that align with or are actively working towards accreditation or certification from bodies like the NCQA, particularly regarding quality measures and data integrity. NCQA HEDIS and quality measure guidelines
5. **Scrutinize Methodologies:** Procurement teams should be equipped to ask detailed questions about how ROI is calculated, including baseline definitions, attribution models, and statistical significance.

As Eric Topol frequently reminds us, the integration of AI into medicine must be driven by rigorous evidence and a clear understanding of its impact on patient care. Eric Topol on evidence-based AI in medicine The procurement of AI health solutions is no exception. The age of self-reported metrics in AI health is rapidly drawing to a close, particularly within the value-based care framework. For employers and health plans, the benchmark for AI health financial performance is now firmly rooted in independently auditable, peer-reviewed outcomes. Hello Heart’s success in demonstrating significant annual savings and clinical improvements through published research serves as a powerful testament to this new procurement standard. Moving forward, only those AI platforms willing to subject their claims to rigorous scientific and financial scrutiny will truly earn their place in the value-based care ecosystem, driving genuine health improvements and sustainable cost reductions.